Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei LPC09
- Development stage
- Preclinical
- Lead developer
- Probiotical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei LPC09 (also classified as Lacticaseibacillus paracasei LPC09) is a probiotic bacterial strain developed and manufactured by Probiotical. It is primarily utilized for its high oxalate-degrading activity, which helps reduce intestinal absorption of oxalates and prevent hyperoxaluria, thereby lowering the risk of calcium oxalate kidney stone formation and crystalluria. Additionally, LPC09 exhibits antagonistic activity against common uropathogens such as Escherichia coli, making it useful in the management and prevention of urinary tract infections (cystitis) and chronic bacterial prostatitis. It is often formulated in probiotic blends (such as Bificist and Bifiprost) alongside other lactobacilli, plant extracts, or D-mannose.
- Other names
- Lacticaseibacillus paracasei LPC09Lactobacillus paracasei subsp. paracasei LPC09
Beyond the preview
Go deeper on Lactobacillus paracasei LPC09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei LPC09.